Topical Calcitriol (BPM31543) for the Prevention of Chemotherapy-Induced Alopecia: Efficacy Findings from a Phase I Safety Study
May 2016
in “
Journal of Clinical Oncology
”
TLDR Topical calcitriol may reduce hair loss from chemotherapy at higher doses.
The study investigated the safety and efficacy of topical calcitriol (BPM31543) in preventing chemotherapy-induced alopecia (CIA) in up to 31 adult women undergoing taxane-based chemotherapy. The treatment involved applying BPM31543 to the scalp twice daily, starting at least 5 days before chemotherapy and continuing for up to 3 months. Results from 21 enrolled subjects (13 evaluable) indicated that the treatment was safe and tolerable, with mild to moderate adverse events. Hair loss was observed in all subjects, but those at higher dosing levels (≥ 20 μg/mL) experienced less severe hair loss, with only 43% showing ≥ 75% hair loss compared to 85% at lower doses (5/10 μg/mL). The study concluded that topical BPM31543 showed potential activity in reducing CIA at higher doses.